



RCSI

UNIVERSITY
OF MEDICINE
AND HEALTH
SCIENCES

Royal College of Surgeons in Ireland

repository@rcsi.com

Farnesoid X receptor agonists attenuate colonic epithelial secretory function and prevent experimental diarrhoea in vivo.

AUTHOR(S)

Magdalena S. Mroz, Niamh Keating, Joseph B. Ward, Rafiquel Sarker, Silvie Amu, Gabriella Aviello, Mark Donowitz, Padraic G. Fallon, Stephen Keely

CITATION

Mroz, Magdalena S.; Keating, Niamh; Ward, Joseph B.; Sarker, Rafiquel; Amu, Silvie; Aviello, Gabriella; et al. (2014): Farnesoid X receptor agonists attenuate colonic epithelial secretory function and prevent experimental diarrhoea in vivo.. Royal College of Surgeons in Ireland. Journal contribution.
<https://hdl.handle.net/10779/rcsi.10786373.v2>

HANDLE

[10779/rcsi.10786373.v2](https://hdl.handle.net/10779/rcsi.10786373.v2)

LICENCE

CC BY-NC-SA 4.0

This work is made available under the above open licence by RCSI and has been printed from <https://repository.rcsi.com>. For more information please contact repository@rcsi.com

URL

https://repository.rcsi.com/articles/journal_contribution/Farnesoid_X_receptor_agonists_attenuate_colonic_epithelial_secretory_function_and_prevent_experimental_diarrhoea_in_vivo_/10786373/2

Farnesoid X Receptor Agonists Attenuate Colonic Epithelial Secretory
Function and Prevent Experimental Diarrhoea in vivo

Magdalena Mroz¹, Niamh Keating¹, Joseph Ward¹, Rafiquel Sarker², Silvie Amu³, Gabriella Aviello³, Mark Donowitz², Padraic Fallon³ and Stephen Keely¹

¹ Department of Molecular Medicine, RCSI Education and Research Centre, Smurfit Building, Beaumont Hospital, Dublin 9, Ireland

² Division of Gastroenterology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.

³ Biomedical Sciences Institute, School of Biochemistry and Immunology, Trinity College Dublin, Ireland

Running title: FXR agonists attenuate colonic secretory function

Abbreviations: cAMP, adenosine 3',5'-cyclic monophosphate; CCh, carbachol; CFTR, cystic fibrosis transmembrane conductance regulator; DCA, deoxycholic acid; EHC, enterohepatic circulation; ENaC, epithelial sodium channel; FGF19, fibroblast growth factor 19; FGFR, fibroblast growth factor receptor; FXR, farnesoid X receptor; FSK, forskolin; IBD, inflammatory bowel disease; IBS, irritable bowel syndrome; I_{Cl}^{apical} , CFTR-mediated currents; I_{sc} , short circuit current; NKCC1, $Na^+/K^+/2Cl^-$ -cotransporter; NHE3, Na^+/H^+ exchanger 3; NMDG, N-methyl-D-glucamine; OVA, ovalbumin; PBS, phosphate-buffered saline; PMSF, phenylmethylsulfonyl fluoride; SGLT, sodium glucose transporter; TER, transepithelial resistance.

Address for correspondence: Stephen J. Keely. Molecular Medicine Laboratories, RCSI Education and Research Centre, Smurfit Building, Beaumont Hospital, Dublin 9. Ireland. Tel: +353 1 809 3821; Fax: +353 1 809 3778; e-mail: skeely@rcsi.ie

Keywords: Epithelial transport, cystic fibrosis transmembrane conductance regulator, Na^+/K^+ ATPase pump, Cl^- secretion, diarrhoea

Word Count: 4405

ABSTRACT

Objective: Bile acids are important regulators of intestinal physiology and the nuclear bile acid receptor, farnesoid X receptor (FXR), is emerging as a promising therapeutic target for several intestinal disorders. Here, we investigated a role for FXR in regulating intestinal fluid and electrolyte transport and the potential for FXR agonists in treating diarrhoeal diseases.

Design: Electrogenic ion transport was measured as changes in short-circuit current across voltage-clamped T₈₄ cell monolayers or mouse tissues in Ussing chambers. NHE3 activity was measured as BCECF fluorescence in Caco-2 cells. Protein expression was measured by immunoblotting and cell surface biotinylation. Antidiarrhoeal efficacy of GW4064 was assessed using 2 *in vivo* mouse models: the ovalbumin-induced diarrhoea model and cholera toxin (CTX)-induced intestinal fluid accumulation. **Results:** GW4064 (5 $\mu\text{mol/L}$; 24 hrs), a specific FXR agonist, induced nuclear translocation of the receptor in T₈₄ cells and attenuated Cl⁻ secretory responses to both Ca²⁺ and cAMP-dependent agonists. GW4064 also prevented agonist-induced inhibition of NHE3 in Caco-2 cells. In mice, intraperitoneal administration of GW4064 (50 mg/mL) also inhibited Ca²⁺ and cAMP-dependent secretory responses across *ex vivo* colonic tissues and prevented ovalbumin-induced diarrhoea and CTX-induced intestinal fluid accumulation *in vivo*. At the molecular level, FXR activation attenuated apical Cl⁻ currents by inhibiting expression of CFTR channels and inhibited basolateral Na⁺/K⁺-ATPase activity without altering expression of the protein. **Conclusion:** These data reveal a novel antisecretory role for the FXR in colonic epithelial cells and suggest that FXR agonists have excellent potential for development as a new class of antidiarrheal drugs.

SUMMARY BOX

What is already known about this subject:

- Although diarrhoeal diseases are common and debilitating conditions, safe and effective drugs for their treatment are still lacking.
- Diarrhoeal diseases primarily occur as a consequence of dysregulated epithelial ion transport, with increased Cl⁻ secretion being the main driving force for fluid secretion into the intestine.
- The nuclear bile acid receptor, farnesoid X receptor (FXR), is emerging as an important regulator of intestinal function and is generating a great deal of interest as a new therapeutic target. However, its role in regulating intestinal fluid and electrolyte transport is still unknown.

What are the new findings:

- Agonists of the FXR inhibit Cl⁻ secretion across colonic epithelial cells in vitro and in vivo
- FXR agonists prevent intestinal fluid secretion and the occurrence of diarrhoea in mouse models of disease
- At the molecular level, FXR agonists exert their antisecretory actions by inhibiting the activity and expression of key transport proteins of the epithelial secretory pathway

How might it impact on clinical practice in the foreseeable future?

- FXR agonists are already under development for treatment of liver and intestinal diseases, and here we show that they also have excellent potential for development as a new class of antidiarrhoeal drug.
- Because FXR agonists exert their antidiarrhoeal actions at the level of epithelial fluid and electrolyte transport, they may be associated with broader efficacy and fewer side effects than currently available drugs.

INTRODUCTION

Intestinal disorders associated with diarrhoea remain a global problem. According to the World Health Organization, there are about 2 billion cases of diarrhoea each year, with their occurrence being most common in developing countries due to the prevalence of infectious disease.¹ Although rarely fatal, epidemics of acute infectious diarrhoea are also common in Western societies,² as are intestinal disorders associated with chronic diarrhoea, including inflammatory bowel diseases (IBD), digestive disorders, and irritable bowel syndrome (IBS).³ Such conditions have significant negative impacts on patient quality of life and represent a huge financial burden to society in terms of healthcare and lost hours of work. However, despite their prevalence, there are still limited options for treating diarrhoeal disease, and no drugs are currently available which directly target the epithelial transport processes underlying dysregulated fluid movement.

Intestinal fluid movement is driven by osmotic gradients established by epithelial ion transport. While fluid absorption is primarily driven by cation absorption, secretion is driven by anions, predominantly Cl^- . The molecular pathway for Cl^- secretion has been well-elucidated and is typically stimulated by neuroimmune agonists that elevate intracellular levels of the prosecretory 2nd messengers, Ca^{2+} and cAMP.⁴ Cl^- enters epithelial cells, along with Na^+ and K^+ , through $\text{Na}^+/\text{K}^+/\text{2Cl}^-$ -cotransporters (NKCC1) in the basolateral membrane. The energy to drive this process comes from the activity of Na^+/K^+ -ATPase pumps, which pump Na^+ from the cell in exchange for K^+ . K^+ does not accumulate intracellularly since it exits through the basolateral channels, KCNN4 and KCNQ1. Thus, the combined activity of these basolateral transport proteins serves to create an electrochemical driving force for Cl^- secretion through channels in the apical membrane, the most characterised of which is the cystic fibrosis transmembrane conductance regulator (CFTR). Molecular mechanisms that regulate the activity and expression of these transport proteins are of great interest since they provide excellent targets for the development of new anti-diarrhoeal therapies.

Bile acids are currently receiving a great deal of interest as targets for the development of new therapeutics for intestinal disease.⁵⁻⁶ The primary bile

acids, chenodeoxycholic acid (CDCA) and cholic acid (CA), are synthesised in the liver and stored in the gallbladder in their glycine- or taurine-conjugated forms. Upon ingestion of a meal, they are released into the proximal small intestine where they perform their classical functions in facilitating lipid digestion and absorption. Most of the released bile acids are reabsorbed in the terminal ileum and returned to the liver via the portal circulation. However, with each cycle of the enterohepatic circulation (EHC), approximately 5% of circulating bile acids enter the colon, where they are metabolised to secondary bile acids, the most common of which is deoxycholic acid (DCA).⁷ In the colon, bile acids act as hormones that regulate many aspects of epithelial physiology, including cell growth, mucus production, barrier function, and production of inflammatory cytokines.⁸⁻¹¹ A growing body of evidence suggests that a nuclear receptor for bile acids, the farnesoid X receptor (FXR), is a critical mediator of epithelial responses to bile acids. This has led to a great deal of interest in therapeutically targeting the FXR, and indeed, synthetic agonists of the receptor have been shown to exert protective effects in an animal model of colitis.¹²

Bile acids are also important regulators of intestinal fluid and electrolyte transport.¹³ In conditions associated with bile acid malabsorption, their delivery to the colon at high concentrations induces fluid and electrolyte secretion,¹⁴ thereby causing diarrhoea.¹⁵⁻¹⁶ However, we have recently shown that, at physiologically-relevant concentrations, bile acids chronically downregulate colonic secretory function, an effect that may serve to facilitate normal colonic absorptive function.¹⁷ Here, we set out to examine the role of the FXR in regulating colonic epithelial fluid and electrolyte transport and the potential for targeting FXR in treatment of diarrhoeal disease.

Materials and Methods

Cell culture. T₈₄ colonic epithelial cells were cultured as previously described.²² For electrophysiological measurements, approximately 5×10^5 cells were seeded onto 12 mm Millicel-HA Transwells (Millipore, Bedford, MA). For Western blotting, approximately 10^6 cells were seeded onto 30 mm Millicel-HA Transwells. Cells were cultured on Transwells for 10–28 days and under these conditions, they developed the polarised, electrically-resistant phenotype of native colonic epithelia. GW4064 (Tocris Bioscience, Bristol, UK) or obeticholic acid (OCA; gifted from Intercept Pharmaceuticals, New York) were used to activate the FXR.¹⁸ Prior to treatment, T₈₄ monolayers were equilibrated in serum-free medium for 2 hrs, and unless otherwise noted, were treated bilaterally with FXR agonists for 24 hrs prior to experimentation.

Animal studies. Male C57BL/6 mice (6–9 weeks old) were maintained in an environmentally-controlled facility at Beaumont Hospital. GW4064 (50 mg/kg), prepared in a DMSO/corn oil mix (1:10, v/v), was injected intraperitoneally (IP). The control group received vehicle alone. Mice were sacrificed 24 hrs later by cervical dislocation, their distal colon or jejunum was removed, and ion transport was measured in Ussing chambers. All experiments were approved by the RCSI Research Ethics Committee.

The mouse model of allergic diarrhoea was based on a previously published protocol.¹⁹ Male BALB/c mice were sensitised twice, 2 weeks apart, by IP injection of 50 mg ovalbumin (OVA) with 1 mg aluminium potassium sulfate adjuvant. 2 weeks later, mice were fasted for 4 hrs and then administered 50 mg OVA, or PBS vehicle, by oral gavage. Mice were challenged with OVA in this way every second day for 2 weeks. Mice were treated with intraperitoneal GW4064 (50 mg/kg), or vehicle, 24 hrs before each oral OVA challenge. Mice demonstrating profuse liquid stool were recorded as being diarrhoea-positive.

Measurements of cholera toxin (CTX)-induced intestinal fluid accumulation were carried out as previously described.²⁰ (Lin et al, 2011). Briefly, male BALB/C mice, weighing 23-26 g, were fasted overnight with free access to water. GW4064 (50 mg/kg) was administered intraperitoneally 24 and 1 hrs before CTX. Mice were then treated by oral gavage with CTX (10 μ g in 7 % NaHCO₃, 0.1 ml/mouse). After 6 hrs mice were euthanised by cervical dislocation, the small intestine (pylorus to the ileocecal junction) was removed, and luminal fluids were collected.

Electrophysiological measurements. For measurements of transepithelial Cl⁻ secretion, T₈₄ cell monolayers or mouse distal colon, stripped of underlying smooth muscle, were mounted in Ussing chambers (aperture = 0.6 cm² or 0.3 cm², respectively) and bathed in Ringer's solution containing (in mmol/L): 40 Na⁺, 5.2 K⁺, 1.2 Ca²⁺, 1.2 Mg²⁺, 119.8 Cl⁻, 25 HCO₃⁻, 0.4 H₂PO₄⁻, 2.4 HPO₄²⁻, and 10 glucose. Tissues were voltage-clamped to zero potential difference and monitored for changes in short circuit current (ΔI_{sc}). Agonist-induced responses were expressed as ΔI_{sc} (μ A/cm²).

Jejunal Na⁺-glucose cotransport was measured as previously described.²¹ Intact (unstripped) tissues were mounted in Ussing chambers (aperture = 0.5 cm²) and bathed in modified Ringer's solution, in which 10 mmol/L glucose was substituted basolaterally with 5 mmol/L glucose and apically with 5 mmol/L mannitol. Na⁺-glucose cotransport was stimulated by apical addition of 25 mmol/L glucose, with mannitol (25 mmol/L) being added basolaterally to maintain iso-osmolarity.

Na⁺/K⁺-ATPase activity was measured as previously described.²² Briefly, T₈₄ cell monolayers were mounted in Ussing chambers and bathed bilaterally in low-sodium (25 mmol/L) Ringer's solution, with NaCl substituted by equimolar N-methyl-D-glucamine (NMDG)-Cl⁻. Apical membranes were permeabilised with amphotericin B (50 μ mol/L). Under these conditions changes in I_{sc} reflect electrogenic transport through Na⁺/K⁺-ATPase pumps, as reflected by their sensitivity to ouabain (10 μ mol/L).

Measurements of cAMP-dependent Cl⁻ currents were carried out using a protocol described by Hallows and colleagues.²³ Basolateral membranes were permeabilised with nystatin (100 µg/ml) and the basolateral Ringer's solution was replaced with a low Cl⁻ solution, containing 25 mmol/L NaCl and 95 mmol/L Na⁺-gluconate, to establish an apical-to-basolateral Cl⁻ concentration gradient. An apical-to-basolateral gradient is usually employed in these experiments in order to prevent cell swelling. Under these conditions, changes in I_{sc} after stimulation with forskolin (FSK) reflect CFTR-mediated currents I_{Cl(apical)}.

Western blotting. Measurements of protein expression were carried out as previously described.²⁴ Antibodies used in the current studies were: rabbit anti-FXR (1:1000 dilution; Santa Cruz, Inc., Santa Cruz, CA), mouse anti-Na⁺/K⁺-ATPase α subunit (1:1000 dilution or 1:500 dilution for biotinylation studies) or mouse anti β subunit (1:1000 dilution; Abcam Inc, Cambridge, MA), and mouse anti-CFTR, clone M3A7 (1:500 dilution and 1:300 dilution for biotinylation studies; Millipore, Billerica, MA). Protein expression was quantified by densitometry.

Surface protein expression. Cell monolayers were washed with PBS and then incubated with Ez-link® Sulfo-NHS-Biotin solution (1mg/ml in PBS; Thermo Fisher Scientific, Waltham, MA), followed by incubation with 100 mmol/L glycine for 15 min, to quench the reaction. Cells were lysed and, after adjusting for protein content, lysates were incubated overnight on a rotator at 4°C with streptavidin-agarose beads. Samples were centrifuged, the supernatant removed, and the agarose beads were washed with lysis buffer. The beads were then resuspended in 2x loading buffer and samples were analyzed by western blotting.

Extraction of nuclear proteins. Treated cells were scraped into ice-cold buffer A (10 mmol/L Hepes (pH = 7.9), 1.5 mmol/L MgCl₂, 10 mmol/L KCl, Complete Protease Inhibitor Cocktail, 0.5 mmol/L PMSF, and 0.5 mmol/L

DTT) and cell suspensions were centrifuged, resuspended in buffer B (buffer A supplemented with 0.1% NP-40), and incubated for 10 min. Samples were centrifuged and supernatants, containing cytosolic proteins, were collected. Pellets were washed in buffer A, centrifuged, resuspended in buffer C (20 mmol/L Hepes (pH = 7.9), 420 nmol/L NaCl, 1.5 mmol/L MgCl₂, 0.2 mmol/L EDTA, 25% glycerol, Complete Protease Inhibitor Cocktail, 0.5 mmol/L PMSF, and 0.5 mmol/L DTT), and incubated on ice for 10 minutes. Samples were centrifuged and the supernatant, containing nuclear proteins, was collected. FXR levels in cytosolic and nuclear fractions were then analyzed by western blotting.

Na⁺/H⁺ exchange activity. Na⁺/H⁺ exchange activity in polarised Caco-2/bbe cells expressing Adeno-HA-NHE3 was determined using the intracellular pH-sensitive dye BCECF, as previously described.²⁶ Cells were treated with GW4064 (5 μmol/L) for 24 hrs prior to conducting the assay. Initial rates of Na⁺-dependent intracellular alkalinization (efflux of H⁺, in micromoles per second) in response to carbachol (10 μM) were calculated for a given pH over ~ 1 min during the initial linear period of intracellular alkalinization. Data were expressed as ΔpH/ΔT.

mRNA expression. RNA was extracted using RNeasy® Mini-Kits (Roche Diagnostics), according to the manufacturer's protocol. cDNA was synthesised by reverse transcription using the Improm-II Reverse Transcription kit (Promega, Madison, WI) and was then used for PCR reactions using GoTaq® green master mix (Promega). The sequences of primers used were: FGF19 (forward: 5'- GAGGACCAAACGAACGAAATT-3', reverse 5'-ACGTCCTTGATGGCAATCG-3', 18s rRNA forward 5'-GTCCCCCAACTTCTTAGAG-3' reverse 5'-CACCTACGGAAACCTTGTTAC-3' (Invitrogen, Carlsbad, CA).

ATP levels. Cell monolayers were lysed in hypotonic lysis buffer (100 mmol/L Tris base, 2 mmol/L EDTA, pH adjusted to 7.5 with acetic acid) and ATP levels were measured using a commercially-available kit (ENLITEN® ATP

Assay System, Promega). ATP levels were normalised to total protein concentration.

Statistical analyses. Data are expressed as mean \pm SE for a series of n experiments. Paired t-tests or one-way analysis of variance (ANOVA) with the Student Neuman–Keuls post test were employed as appropriate. p values \leq 0.05 were considered to be statistically significant.

RESULTS

FXR activation inhibits Cl⁻ secretion in T₈₄ cells

The FXR agonist, GW4064 (5 $\mu\text{mol/L}$), significantly increased nuclear localization of FXR to $369 \pm 70\%$ of that in control cells after 6 hrs ($n = 4$; $p < 0.05$) (Figure 1A). Confocal analysis of GW4064-treated cells confirmed increased FXR staining in the nucleus (Figure 1B). Furthermore, treatment of T₈₄ cell monolayers with GW4064 (5 $\mu\text{mol/L}$) robustly increased expression of the FXR target gene, FGF19 (Figure 1C), demonstrating that the agonist effectively activates FXR in these cells.

To determine the effects of FXR activation on colonic epithelial secretory function, T₈₄ cell monolayers were treated with GW4064 (5 $\mu\text{mol/L}$; 24 hrs), mounted in Ussing chambers and Cl⁻ secretion was stimulated with the prototypical, Ca²⁺ and cAMP-dependent agonists, CCh (100 $\mu\text{mol/L}$) and FSK (10 $\mu\text{mol/L}$), respectively. GW4064 significantly reduced CCh- and FSK-stimulated currents to $38 \pm 6\%$ ($n = 9$; $p < 0.01$) and $52 \pm 5\%$ ($n = 9$; $p < 0.001$) of control responses, respectively (Figures 2A and 2B). Antisecretory effects of GW4064 were observed at concentrations as low as 0.1 $\mu\text{mol/L}$ (Figure 2B) and were apparent after 12 hrs of treatment (Figure 2C). In similar experiments, FXR activation also decreased Cl⁻ secretion induced by the naturally-occurring secretagogues, DCA (500 $\mu\text{mol/L}$) and cholera toxin (CTX; 0.1 $\mu\text{g/ml}$) to $64 \pm 10\%$ ($n = 8$; $p < 0.05$) and $81 \pm 6\%$ ($n = 7$; $p < 0.05$) of controls, respectively. The effects of GW4064 were not due to cellular toxicity as it did not alter transepithelial resistance (TER), nor did it cause lactate dehydrogenase release, which in GW4064 (5 $\mu\text{mol/L}$)-treated cells was $107 \pm 10\%$ of that in controls ($n = 4$). Furthermore, antisecretory actions were not specific to GW4064, since a structurally distinct FXR agonist, OCA (6-ethyl-CDCA), also attenuated secretory responses to CCh and FSK (Figure 2D).

We also examined effects of FXR activation on electrogenic Na⁺ absorption through ENaC, which represents the major route for Na⁺ absorption in human distal colon. Since there are no cellular models available that are suitable for measurements of intestinal epithelial ENaC activity, we used a previously-described model, in which treatment of T₈₄ cells with 4-

phelylbutyrate (5 mmol/L; 24 hrs) reliably induces expression of the channel.²⁵ We also found 4-phelylbutyrate to induce expression of the ENaC α subunit (data not shown) in T₈₄ cells and amiloride-sensitive currents in T₈₄ cells. However, these currents were unaffected by co-treatment of the cells with GW4064 (n = 4; Figure 2E).

Sodium-hydrogen exchange (NHE) is also an important mechanism of fluid absorption throughout the intestine and, in humans, is mediated predominantly by apical NHE3. Using a well-established Caco-2 cell model,²⁶ we found that treatment with GW4064 did not significantly alter basal NHE3 activity, but prevented inhibition of the transporter by CCh (Fig 2F).

FXR activation inhibits fluid and electrolyte secretion *in vivo*

To test effects of FXR activation on epithelial transport in a more physiological setting, mice were treated by IP injection with GW4064 (50 mg/kg) and after 24 hrs, colonic tissues were mounted in Ussing chambers. Transmucosal resistance were similar in colonic tissues from control and GW4064-treated mice (data not shown). However, Cl⁻ secretory responses to CCh and FSK in tissues from treated mice were significantly reduced to 79 ± 6 (p < 0.001) and $77 \pm 7\%$ (p < 0.01) of those in control tissues, respectively (n = 11; Figure 3A). In contrast, Na-glucose cotransport, stimulated by apical addition of glucose (25 mmol/L) to jejunal tissues from these mice, was unaltered by GW4064 treatment (Figure 3B).

Next, we examined the effects of GW4064 in 2 different mouse models of diarrhoeal disease. In the first model of allergic disease, oral challenge with ovalbumin induced severe diarrhoea in 100% of presensitised mice, as evidenced by the lack of solid stool in the colons of these mice compared to controls (Figure 3C). In contrast, in mice pretreated with GW4064 (50 mg/kg), diarrhoea occurrence was markedly attenuated and solid stool pellets could be clearly observed in the colons from these animals (n = 10). In the second model, we found that GW4064 also prevented the prosecretory effects of CTX in an *in vivo* model of intestinal fluid accumulation (Figure 3D). In mice treated with CTX alone, fluid accumulation in the small

intestine was 0.41 ± 0.04 mL, compared to 0.25 ± 0.04 mL in mice pretreated with GW4064 ($n = 9$; $p < 0.05$). Fluid accumulation in untreated control mice was 0.03 ± 0.01 mL ($n = 3$).

FXR activation inhibits Na^+/K^+ -ATPase activity and CFTR Cl^- currents in colonic epithelial cells

Having found FXR activation to inhibit colonic fluid and electrolyte secretion *in vivo*, we returned to our *in vitro* model to begin to elucidate molecular mechanisms involved. Using a well-established protocol for measuring Na^+/K^+ -ATPase transport function,²² we found that GW4064 inhibited transport activity of the pump to $61 \pm 10\%$ of that in control cells ($n = 6$; $p < 0.05$) (Figure 4A). Interestingly, this inhibitory effect was not associated with altered expression of either the catalytic α , or regulatory β , subunits of the protein (Figure 4B). Furthermore, using a biotinylation approach to label cell surface proteins in the basolateral membrane, we found that membrane expression of the α subunit was not altered in GW4064-treated cells (Figure 4C). No β -actin was detected in the biotinylated protein fraction, confirming specific isolation of surface proteins ($n = 3$). Furthermore, cellular ATP, which is required to drive Na^+/K^+ -ATPase transport activity, was found to be unaltered by FXR activation, with levels of ATP in GW4064-treated cells being $96 \pm 13\%$ of those in controls ($n = 6$).

Finally, we examined the effects of FXR activation on apical CFTR channels, which constitute the primary exit pathway for Cl^- in colonic epithelial cells²³. In these experiments, we found that FSK-induced CFTR currents were attenuated by pretreatment of the cells with GW4064 ($5 \mu\text{mol/L}$, 24 hrs) (Figure 5A). Interestingly, GW4064 inhibition of CFTR-mediated Cl^- currents was associated with a significant decrease in CFTR protein expression to $33 \pm 9\%$ of that in controls ($n = 4$; $p < 0.001$) (Figure 5B), while apical surface expression of the protein was reduced to $35 \pm 6\%$ of controls ($n = 4$; $p < 0.001$) (Figure 5C).

DISCUSSION

There is currently a great deal of research interest in the therapeutic potential of the FXR. Agonists of this nuclear receptor are already in advanced clinical trials for treatment of liver diseases,²⁷ and they have also been proposed as potential targets for therapy of several other conditions, including obesity, type 2 diabetes, atherosclerosis, and IBD.^{28,12} The current studies suggest that, due to their potent antisecretory actions on intestinal epithelial cells, FXR agonists may also be beneficial in treatment of intestinal disorders associated with secretory diarrhoea. We found that 2 structurally unrelated FXR agonists, GW4064 and OCA, attenuated both Ca^{2+} - and cAMP-dependent Cl^- secretory responses across cultured colonic epithelia. Furthermore, *ex vivo* colonic tissues from GW4064-treated mice also displayed attenuated responsiveness to secretagogues. Since Cl^- secretion is the primary driving force for fluid secretion in the intestine, on the basis of our data one would expect that FXR agonists should reduce fluid movement into the lumen. This hypothesis was borne out by our experiments in a murine model of allergic diarrhoea. Intestinal fluid loss in this model has been previously shown to be due to secretory diarrhoea,²⁹ and was reversed by pretreatment of the mice with GW4064. Further support for this hypothesis comes from our studies showing that GW4064 prevents small intestinal fluid accumulation in an *in vivo* model of CTX-induced secretion. Thus, FXR agonists exert antisecretory effects *in vitro*, *ex vivo*, and *in vivo*, suggesting that they could be useful in the treatment of diarrhoeal diseases. It should be noted that although the G protein-coupled bile acid receptor, TGR5, is also expressed in colonic epithelia,³⁰ it is unlikely contribute to the antisecretory actions of FXR agonists, described here. Firstly, FXR and TGR5 have distinct ligand binding characteristics,³¹ with FXR agonists, such OCA, being poor agonists of TGR5, and secondly, we have recently published data which show that TGR5 activation with INT-777, a poor agonist of FXR, exerts actions in colonic epithelial cells distinct to those described here for FXR agonists.³¹

The antisecretory effects of FXR agonists appear to be due to inhibition of multiple components of the epithelial Cl^- secretory pathway, with both

basolateral Na^+/K^+ ATPase activity and apical CFTR Cl^- channel currents being attenuated upon treatment. Thus, activation of the FXR prevents fluid secretion by inhibiting both the driving force for Cl^- uptake across the basolateral membrane, and its exit across the apical membrane. Furthermore, the effects of FXR activation on inhibition of transport protein function appear to be specific, since basolateral K^+ channel currents, which are necessary to drive Cl^- secretion, were found to be unaltered by GW4064 (data not shown). Thus, the effects of GW4064 do not appear to be due to a loss of cell viability, and this is further supported by observations that, even at the highest concentrations tested, GW4064 did not alter TER or LDH release from cultured cells, nor did it have any apparent toxicity in vivo. Furthermore, at concentrations similar to those used in the current study, previous studies have shown that GW4064 is devoid of liver and kidney toxicity.³²⁻³³

Interestingly, mechanisms underlying FXR-induced inhibition of CFTR currents and Na^+/K^+ ATPase activity appear to be different. Inhibition of CFTR Cl^- currents was associated with attenuated cellular expression of the protein, accompanied by a decrease in its cell surface expression. Notably, the degree to which FXR activation inhibited CFTR surface expression was somewhat greater than its effects on apical Cl^- currents, which correlates with previous studies demonstrating that there is an excess of CFTR expressed in intestinal epithelia and that more than 60% inhibition of its expression is necessary before altered Cl^- secretory responses are observed. How, FXR activation might bring about alterations in CFTR expression remain to be determined. However, our preliminary, unpublished, data show that GW4064 also downregulates CFTR mRNA expression, suggesting its effects are likely mediated either at the transcriptional or post-transcriptional level. In contrast, FXR-induced inhibition of Na^+/K^+ ATPase activity was not associated with altered expression of either the catalytic α or regulatory β subunits of the protein. Furthermore, activation of the FXR did not alter cellular levels of ATP which is required to drive Na^+/K^+ ATPase activity. Thus, it seems likely that FXR actions on Na^+/K^+ ATPase transport activity involves intermediary proteins that regulate pump activity. A number of such proteins exist, including a family of FXYD proteins,³⁴ and modulator of Na^+/K^+ ATPase.³⁵ Such

proteins are expressed in a cell specific manner, thereby enabling differential regulation of Na⁺/K⁺ ATPase activity in different cell types, and our preliminary studies show that they are expressed in colonic epithelial cells (data not shown). Future studies will aim to more precisely elucidate the molecular mechanisms involved in FXR-induced regulation of CFTR expression and Na⁺/K⁺ ATPase activity.

In the current studies we also examined the effects of FXR activation on absorptive processes. In the intestine, electrogenic Na⁺ absorption through ENaC, electroneutral absorption through NHE3, and Na⁺-glucose cotransport through SGLT1 are the primary mechanisms driving fluid absorption. Using a number of different models to measure their activity, we found that FXR activation was without effect on the activity of any of these transport proteins under basal conditions. However, we found that treatment with GW4064 reversed agonist-induced inhibition of NHE3 activity. This is important since many prosecretory agonists, typified by CCh, are known to simultaneously inhibit absorption through NHE3,³⁶ an effect which would serve to enhance fluid accumulation in the lumen. Thus, *in vivo*, FXR agonists would be expected to prevent the onset of diarrhoea, not only through inhibition of secretory responses, but also through promotion of absorption. How FXR activation prevents secretagogue-induced inhibition of NHE3 remains to be determined. However, previous work has shown that inhibition of NHE3 activity by Ca²⁺-dependent agonists, such as CCh, is mediated by endocytosis of the transporter from the cell surface.³⁷ Thus, since FXR activation does not alter basal NHE3 activity, it is unlikely that FXR agonists act by increasing cellular expression of the protein, but rather by interfering with the inhibitory pathway induced by CCh. Future studies will aim to more thoroughly investigate this hypothesis.

Thus, our data suggest that FXR agonists prevent fluid accumulation in the intestine through pathways that ultimately inhibit Na/K ATPase activity and CFTR expression, and which also prevent secretagogue-induced inhibition of absorption through NHE3. An intriguing question that arises from these studies is how activation of the FXR can have such diverse effects on different transport processes. The answer to this question likely lies in the ability of the

FXR to regulate cellular processes through multiple mechanisms. For example, activated FXR may regulate epithelial transport by binding to FXR response elements on genes encoding either transport proteins or the regulatory proteins that control their activity. Alternatively, FXR activation could downregulate the expression transporters, or their regulatory proteins, through a number of mechanisms, including binding to negative response elements within the promoter regions of their genes, induction of DNA methylation, or stimulating expression of miRNAs that specifically target the mRNA for these proteins. Each of these mechanisms has been shown to mediate FXR actions in other cell types,³⁸⁻⁴⁰ and future studies will aim at elucidating these complex FXR-dependent signalling pathways in intestinal epithelial cells and their potential involvement in regulation of fluid and electrolyte transport.

While most currently available antidiarrhoeals exert their effects by indirect mechanisms, FXR agonists inhibit Cl⁻ secretion through direct actions on epithelial cells, and therefore may be useful in treating a range of secretory diarrhoeas. For example, diarrhoea induced by CTX is driven by excessive Cl⁻ secretion through CFTR,⁴¹ and since CFTR expression is downregulated by FXR activation, targeting the receptor as a therapy for cholera-induced diarrhoea may be a useful approach. Recent studies suggest that FXR agonists may also have a role to play in treating a subset of patients diagnosed as having IBS, but who actually suffer from bile acid diarrhoea (BAD). Approximately 30% of all diagnosed IBS patients have the diarrhoea-predominant form, IBS-D,⁴² and it has been recently shown that of these patients, approximately 30% have increased bile acid loss (as measured by SeHCAT retention) and increased bile acid synthesis.⁴³⁻⁴⁴ Interestingly, dysregulation of bile acid biosynthesis in these patients appears to be due to defective production of the FXR target protein, FGF-19, an enterohepatic messenger that downregulates bile acid biosynthesis. Normally, FGF-19 production is induced by bile acids acting on FXR in ileal epithelial cells and loss of this signal leads to enhanced bile acid biosynthesis and increased delivery into the colon. Since bile acids exert prosecretory effects at such pathophysiological concentrations, this induces the onset of diarrhoea. Thus,

one would expect that this particular subset of BAD patients, which constitutes approximately 1% of the population of Western countries,⁴² should benefit doubly by the use of FXR agonists through restoration of FGF-19 production and exertion of antisecretory actions on the colonic epithelium.

In summary, these studies reveal an important role for the FXR in regulating intestinal fluid and electrolyte secretion. The effects of FXR activation are mediated by direct actions at the level of epithelial cells and occur through inhibition of multiple components of the Cl⁻ secretory mechanism. While its precise role in regulating epithelial transport function under normal physiological circumstances remain to be elucidated, our studies suggest that the FXR represents an excellent target for the development of a new class of antidiarrhoeal drugs.

FIGURE LEGENDS

Figure 1. GW4064 activates FXR in colonic epithelial cells. **A)** Monolayers of T₈₄ cells were treated with GW4064 (5 µmol/L) and FXR expression in nuclear and cytosolic fractions was measured after 3, 6 or 24 hrs. FXR expression in the nuclear fraction was normalised to lamin A/C expression and FXR expression in cytosolic fraction was normalised to β-actin (n = 4). Panel **B)** shows densitometric analysis of 4 similar experiments. **C)** Confocal analysis confirmed that GW4064 caused translocation of FXR from the cytosol to the nucleus after 24 hrs of treatment (image is representative of 3 similar experiments). **D)** RT-PCR analysis revealed that the FXR target gene, FGF19, was significantly increased after GW4064 treatment (n = 5). * p < 0.05

Figure 2. FXR activation inhibits colonic epithelial Cl⁻ secretion *in vitro*. **A)** Monolayers of T₈₄ cells were treated with GW4064 (5 µmol/L) for 24 hrs before Cl⁻ secretory responses to CCh (100 µM; basolateral) and FSK (10 µM, apical) were measured in Ussing chambers (n = 8). **B)** T₈₄ cells were exposed to GW4064 at various concentrations for 24 hrs before Cl⁻ secretory responses to CCh and FSK were measured (n = 3–6). **C)** T₈₄ cells were exposed to GW4064 (5 µmol/L) for varying periods of time before subsequent I_{sc} responses to CCh and FSK were measured (n = 3–7). **D)** T₈₄ cells were exposed to OCA at various concentrations for 24 hrs before Cl⁻ secretory responses to CCh (n = 7) and FSK (n = 6) were measured. **E)** T₈₄ cells were treated with GW4064 in presence of sodium 4-phenylbutyrate (5 mmol/L) for 24 hrs. Cells were then mounted in Ussing chambers and amiloride (10 µM) was added apically to inhibit ENaC (n = 4). **F)** Monolayers of Caco-2 cells were treated with GW4064 (5 µmol/L; 24 hrs) and basal and CCh-induced inhibition of NHE3 activity were measured as changes in BCECF fluorescence in response to NHCl₂ (50 mmol/L) (n = 4). * p < 0.05, ** p < 0.01, *** p < 0.001, ns; no significant difference.

Figure 3. FXR activation inhibits colonic epithelial fluid and electrolyte secretion *in vivo*. **A)** Male C57BL/6 mice were treated with GW4064

(intraperitoneal, 50 mg/kg), or vehicle, for 24 hrs after which muscle-stripped sections of distal colon were mounted in Ussing chambers for measurements of CCh (100 $\mu\text{mol/L}$) and FSK (10 $\mu\text{mol/L}$)-stimulated Cl^- secretion. Amiloride (10 $\mu\text{mol/L}$) was present throughout to exclude any contribution of ENaC to observed I_{sc} responses. The left panel shows a mean trace of $n = 11$ experiments and the right panel shows maximal responses to CCh and FSK in GW4064-treated tissues as a percent of controls ($n = 11$). **B)** Intact sections of mouse jejunum from control or GW4064-treated mice were mounted in Ussing chambers and Na^+ -glucose cotransport was stimulated by apical addition of glucose (5 mmol/L). Bumetanide (Bum) (100 $\mu\text{mol/L}$) was present throughout to exclude the contribution of Cl^- secretion to observed responses. Phlorizin, was added at the end of each experiment to confirm that responses were due to Na^+ /glucose exchange through SGLT-1 ($n = 8$). **C)** Ovalbumin-sensitised male Balb/C mice were treated with GW4064 (intraperitoneal, 50 mg/kg) or vehicle and after 24 hrs were challenged by oral gavage with ovalbumin (50 mg). Mice were treated in this way every 2 days, and those demonstrating profuse liquid stool within 1 hr after OVA challenge were recorded as being diarrhoea-positive. The graph shows diarrhoea occurrence as a percent of the number of mice in each group ($n = 10$), while the inset shows a representative image of colons from each group. Note the lack of fecal pellets in ovalbumin-treated mice, indicating diarrhoea, compared to those pretreated with GW4064. **D)** Male Balb/C mice were treated with GW4064 (intraperitoneal, 50 mg/kg) or vehicle and 24 hrs and 1 hrs prior to oral challenge with cholera toxin (CTX). After 6 hrs mice were sacrificed, the small intestine (pylorus – ilieocaecal junction) was removed, and luminal fluid was collected and measured ($n = 10$). * $p < 0.01$; ** $p < 0.01$

Figure 4. FXR activation decreases Na^+/K^+ -ATPase activity in colonic epithelial cells. **A)** GW4064 (5 $\mu\text{mol/L}$; 24 hrs)-treated T_{84} cell monolayers were mounted in Ussing chambers for measurements of Na^+/K^+ -ATPase activity, as described in Methods ($n = 6$). The right panel shows maximal changes in CCh-induced I_{sc} in GW4064-treated cells as a percent of controls. **B)** Cells were treated with GW4064 (5 $\mu\text{mol/L}$; 24 hrs) after which Na^+/K^+ -

ATPase α or β subunit expression were measured by western blotting. Na^+/K^+ -ATPase expression was normalised to β -actin expression. The lower panel shows densitometric analysis of 3 similar experiments. **C)** After treatment with GW4064 (5 $\mu\text{mol/L}$; 24 hrs) Na^+/K^+ -ATPase α subunit was detected by cell surface biotinylation of the basolateral membrane. The lower panel shows densitometric analysis of surface Na^+/K^+ -ATPase α expression from 6 similar experiments. * $p < 0.05$

Figure 5. FXR activation inhibits CFTR currents and protein expression.

A) GW4064 (5 $\mu\text{mol/L}$; 24 hrs)-treated T_{84} cell monolayers were mounted in Ussing chambers for measurements of apical CFTR currents (I_{Cl^-}), as described in Methods ($n = 6$). The right panel shows maximal changes in FSK-induced I_{Cl^-} in GW4064-treated cells as a percent of controls ($n = 9$). **B)** T_{84} cells were treated with GW4064 (5 $\mu\text{mol/L}$; 24 hrs) after which CFTR expression was measured by western blotting. CFTR expression was normalised to β -actin expression. The lower panel shows densitometric analysis of 7 experiments. **C)** After treatment with GW4064 (5 $\mu\text{mol/L}$; 24 hrs) CFTR was detected by biotinylation of the apical membrane. The lower panel shows densitometric analysis of surface CFTR expression from 4 similar experiments. ** $p < 0.01$; *** $p < 0.001$.

ACKNOWLEDGEMENTS: The authors would like to thank Prof. Alan F Hofmann (University of California, San Diego) for his helpful discussion during preparation of this manuscript.

FUNDING: This work was supported by Principal Investigator and TIDA Awards from Science Foundation Ireland to SJK and by the National Biophotonics and Imaging Platform, Ireland.

COMPETING INTERESTS: SJK is a named inventor on a patent granted by the EPO for the use of FXR agonists in treating diarrhoeal diseases (EPO No: 09802112.4)

REFERENCES

1. Baldi F, Bianco MA, Nardone G, et al. Focus on acute diarrhoeal disease. *World J Gastroenterol* 2009;**15**:3341-8.
2. Donowitz M, Alpers DH, Binder HJ, et al. Translational approaches for pharmacotherapy development for acute diarrhea. *Gastroenterology* 2012;**142**:e1-9.
3. Fine KD, Schiller LR. AGA technical review on the evaluation and management of chronic diarrhea. *Gastroenterology* 1999;**116**:1464-86.
4. Barrett KE, Keely SJ. Chloride secretion by the intestinal epithelium: molecular basis and regulatory aspects. *Annu Rev Physiol* 2000;**62**:535-72.
5. Gonzales E, Gerhardt MF, Fabre M, et al. Oral cholic acid for hereditary defects of primary bile acid synthesis: a safe and effective long-term therapy. *Gastroenterology* 2009;**137**:1310-1320 e1-3.
6. Gruy-Kapral C, Little KH, Fordtran JS, et al. Conjugated bile acid replacement therapy for short-bowel syndrome. *Gastroenterology* 1999;**116**:15-21.
7. Zhu Y, Li F, Guo GL. Tissue-specific function of farnesoid X receptor in liver and intestine. *Pharmacol Res* 2011;**63**:259-65.
8. Maran RR, Thomas A, Roth M, et al. Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development. *J Pharmacol Exp Ther* 2009;**328**:469-77.
9. Barcelo A, Claustre J, Toumi F, et al. Effect of bile salts on colonic mucus secretion in isolated vascularly perfused rat colon. *Dig Dis Sci* 2001;**46**:1223-31.
10. Raimondi F, Santoro P, Barone MV, et al. Bile acids modulate tight junction structure and barrier function of Caco-2 monolayers via EGFR activation. *Am J Physiol Gastrointest Liver Physiol* 2008;**294**:G906-13.
11. Saitoh O, Nakagawa K, Sugi K, et al. Bile acids inhibit tumour necrosis factor alpha-induced interleukin-8 production in human colon epithelial cells. *J Gastroenterol Hepatol* 1998;**13**:1212-7.

12. Gadaleta RM, van Erpecum KJ, Oldenburg B, et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. *Gut* 2011;**60**:463-72.
13. Keating N, Keely SJ. Bile acids in regulation of intestinal physiology. *Curr Gastroenterol Rep* 2009;**11**:375-82.
14. Keely SJ, Scharl MM, Bertelsen LS, et al. Bile acid-induced secretion in polarized monolayers of T84 colonic epithelial cells: Structure-activity relationships. *Am J Physiol Gastrointest Liver Physiol* 2007;**292**:G290-7.
15. Mekjian HS, Phillips SF, Hofmann AF. Colonic secretion of water and electrolytes induced by bile acids: perfusion studies in man. *J Clin Invest* 1971;**50**:1569-77.
16. Wingate DL, Phillips SF, Hofmann AF. Effect of glycine-conjugated bile acids with and without lecithin on water and glucose absorption in perfused human jejunum. *J Clin Invest* 1973;**52**:1230-6.
17. Keating N, Mroz MS, Scharl MM, et al. Physiological concentrations of bile acids down-regulate agonist induced secretion in colonic epithelial cells. *J Cell Mol Med* 2009;**13**:2293-303.
18. Maloney PR, Parks DJ, Haffner CD, et al. Identification of a chemical tool for the orphan nuclear receptor FXR. *J Med Chem* 2000;**43**:2971-4.
19. Brandt EB, Strait RT, Hershko D, et al. Mast cells are required for experimental oral allergen-induced diarrhea. *J Clin Invest* 2003;**112**:1666-77.
20. Lin R, Murtazina R, Cha B, et al. D-glucose acts via sodium/glucose cotransporter 1 to increase NHE3 in mouse jejunal brush border by a Na⁺/H⁺ exchange regulatory factor 2-dependent process. *Gastroenterology* 2011;**140**:560-71.
21. Grubb BR. Ion transport across the jejunum in normal and cystic fibrosis mice. *Am J Physiol* 1995;**268**:G505-13.

22. Lam RS, App EM, Nahirney D, et al. Regulation of Cl⁻ secretion by alpha2-adrenergic receptors in mouse colonic epithelium. *J Physiol* 2003;**548**:475-84.
23. Hallows KR, Kobinger GP, Wilson JM, et al. Physiological modulation of CFTR activity by AMP-activated protein kinase in polarized T84 cells. *Am J Physiol Cell Physiol* 2003;**284**:C1297-308.
24. Mroz MS, Keely SJ. Epidermal growth factor chronically upregulates Ca(2+)-dependent Cl(-) conductance and TMEM16A expression in intestinal epithelial cells. *J Physiol* 2012;**590**:1907-20.
25. Iordache C, Duszyk M. Sodium 4-phenylbutyrate upregulates ENaC and sodium absorption in T84 cells. *Exp Cell Res* 2007;**313**:305-11.
26. Khurana S, Nath SK, Levine SA, et al. Brush border phosphatidylinositol 3-kinase mediates epidermal growth factor stimulation of intestinal NaCl absorption and Na⁺/H⁺ exchange. *J Biol Chem* 1996;**271**:9919-27.
27. Adorini L, Pruzanski M, Shapiro D. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. *Drug Discov Today* 2012;**17**:988-97.
28. Thomas C, Pellicciari R, Pruzanski M, et al. Targeting bile-acid signalling for metabolic diseases. *Nat Rev Drug Discov* 2008;**7**:678-93.
29. Perdue MH, Masson S, Wershil BK, et al. Role of mast cells in ion transport abnormalities associated with intestinal anaphylaxis. Correction of the diminished secretory response in genetically mast cell-deficient W/W^v mice by bone marrow transplantation. *J Clin Invest* 1991;**87**:687-93.
30. Ward JB, Mroz MS, Keely SJ. The bile acid receptor, TGR5, regulates basal and cholinergic-induced secretory responses in rat colon. *Neurogastroenterol Motil.* 2013 May 1. [Epub ahead of print]
31. Pellicciari R, Gioiello A, Macchiarulo A, et al. Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabetes. *J Med Chem* 2007; **52**: 7958-61.

32. Liu Y, Binz J, Numerick MJ, et al. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. *J Clin Invest* 2003;**112**:1678-87.
33. Jiang T, Wang XX, Scherzer P, et al. Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy. *Diabetes* 2007;**56**:2485-93.
34. Geering K. Function of FXYD proteins, regulators of Na, K-ATPase. *J Bioenerg Biomembr* 2005;**37**:387-92.
35. Mao H, Ferguson TS, Cibulsky SM, et al. MONaKA, a novel modulator of the plasma membrane Na,K-ATPase. *J Neurosci* 2005;**25**:7934-43.
36. Cohen ME, Wesolek J, McCullen J, et al. Carbachol- and elevated Ca(2+)-induced translocation of functionally active protein kinase C to the brush border of rabbit ileal Na⁺ absorbing cells. *J Clin Invest* 1991;**88**:855-63.
37. Zachos NC, Lee LJ, Kovbasnjuk O, et al. PLC- γ directly binds activated c-Src which is necessary for carbachol-mediated inhibition of NHE3 activity in Caco-2/BBe cells. *Am J Physiol Cell Physiol*. 2013 May 22. [Epub ahead of print]
38. Li J, Zhang Y, Kuruba R, et al. Roles of microRNA-29a in the antifibrotic effect of farnesoid X receptor in hepatic stellate cells. *Mol Pharmacol* 2011, 80:191-200.
39. Rizzo G, Renga B, Antonelli E, et al. The methyl transferase PRMT1 functions as co-activator of farnesoid X receptor (FXR)/9-cis retinoid X receptor and regulates transcription of FXR responsive genes. *Mol Pharmacol* 2005, 68:551-8.
40. Chennamsetty I, Claudel T, Kostner KM, et al. Farnesoid X receptor represses hepatic human APOA gene expression. *J Clin Invest* 2011, 121:3724-34.
41. Gabriel SE, Brigman KN, Koller BH, et al. Cystic fibrosis heterozygote resistance to cholera toxin in the cystic fibrosis mouse model. *Science* 1994;**266**:107-9.
42. Walters JR, Pattni SS. Managing bile acid diarrhoea. *Therap Adv Gastroenterol* 2010;**3**:349-57.

43. Smith MJ, Cherian P, Raju GS, et al. Bile acid malabsorption in persistent diarrhoea. *J R Coll Physicians Lond* 2000;**34**:448-51.
44. Walters JR, Tasleem AM, Omer OS, et al. A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. *Clin Gastroenterol Hepatol* 2009;**7**:1189-94.

Copyright Declaration: The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article to be published in Gut editions and any other BMJPGJL products to exploit all subsidiary rights, as set out in their licence.

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5

